XP-DC vaccinations
Phase 2Biologic
XP-DC vaccinations is one of 49 biologic programs targeting Ovarian Cancer. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
209 competitors in Ovarian Cancer
#DrugCompanyPhaseTrials
1Gemzar
Johnson & JohnsonPhase 3
Keytruda
Merck & Co.Phase 3
Pegylated Liposomal Doxorubicin
Merck & Co.Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Femara
NovartisPhase 3
Opdivo
Bristol-Myers SquibbPhase 3
Adriamycin
PfizerPhase 3
Lynparza
RRisen (Suzhou) Pharma Tech Co., Ltd.
Phase 3
Afinitor
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for XP-DC vaccinations. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details